The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Investigating the impact of demographic disparities on clinical outcomes in cutaneous T-cell lymphoma (CTCL): A multicenter retrospective cohort analysis.
 
Tim Niyogusaba
No Relationships to Disclose
 
Jeffrey M. Switchenko
No Relationships to Disclose
 
Sima Rozati
No Relationships to Disclose
 
Swaminathan Padmanabhan Iyer
Honoraria - Seagen
Consulting or Advisory Role - Legend Biotech; Seagen; Secura Bio; Yingli Pharma
Speakers' Bureau - Targeted Oncology
Research Funding - Affimed Therapeutics (Inst); crispr therapeutics (Inst); Innate Pharma; Legend Biotech ; Merck; Rhizen Pharmaceuticals (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Trillium Therapeutics (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Takeda
 
Sai Talluru
No Relationships to Disclose
 
Auris Huen
No Relationships to Disclose
 
Irl Brian Greenwell
Consulting or Advisory Role - Kite, a Gilead Company; Stemline Therapeutics
 
Jane Scribner
No Relationships to Disclose
 
Sunil Rangarajan
No Relationships to Disclose
 
Amitkumar Mehta
Stock and Other Ownership Interests - WITTY HEALTH
Consulting or Advisory Role - AstraZeneca; BeiGene; Gilead Sciences; Incyte; Incyte; Kyowa Kirin International; Novartis; Pharmacyclics; Roche/Genentech; Seagen; TG Therapeutics
Speakers' Bureau - Adaptive Biotechnologies; BeiGene; Epizyme; Gilead Sciences; Incyte; Kite, a Gilead company; Kyowa Kirin International; Seagen
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Aileron Therapeutics (Inst); Artiva (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Forty Seven (Inst); Gilead Sciences (Inst); I-Mab (Inst); incyte (Inst); Innate Pharma (Inst); Juno Therapeutics (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Pharmacyclics/Janssen (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
 
Anne Beaven
No Relationships to Disclose
 
Safiyah Bhatti
No Relationships to Disclose
 
Shalini Krishanasamy
No Relationships to Disclose
 
Pierluigi Porcu
Honoraria - Celgene; Daiichi Sankyo Pharmaceutical; Innate Pharma; Kyowa Kirin; Viracta Therapeutics
Consulting or Advisory Role - Innate Pharma; Viracta Therapeutics
 
Tarsheen Sethi
No Relationships to Disclose
 
Francine M. Foss
Consulting or Advisory Role - Acrotech Biopharma; Eisai; Eisai; Mallinckrodt; Seagen; Secura Bio
Speakers' Bureau - Seagen
Research Funding - Astex Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kura Oncology (Inst); Kyowa Hakko Kirin (Inst); Miragen (Inst)
 
Darina Paulino
No Relationships to Disclose
 
Katherine Case
No Relationships to Disclose
 
Mary Jo Lechowicz
No Relationships to Disclose
 
Pamela Blair Allen
Consulting or Advisory Role - BostonGene; Daiichi Sankyo Pharmaceutical; Kyowa Kirin; Secura Bio
Research Funding - BostonGene